Thyroid stimulating hormone (TSH) was measured using a highly sensitive cytochemical bioassay (CBA) technique in normal subjects, in patients with Graves' disease (untreated and treated) and in patients with euthyroid goiter and negative thyrotropin-releasing hormone (TRH)-test. Plasma TSH levels of normal subjects and of subjects with untreated Graves' disease were reduced after the plasma had been incubated with a specific antibody to human TSH, indicating that the thyroid stimulating substance measured with this assay was likely to be TSH. Basal TSH levels in patients with Graves' disease and in a special group of patients with euthyroid goiter and negative TRH test were low but detectable. They did not rise after TRH administration. Increased TSH release (4.5- to 10-fold) after TRH stimulation was demonstrated, however, in two formerly hyperthyroid patients after treatment. This increase was not detected by radioimmunoassay (RIA) due to limited sensitivity.

Aged↗

PubMedDate not supplied

Cerebrovascular reactivity to acetazolamide in (senile) dementia of Alzheimer's type: relationship to disease severity.

Neuropathological reports about denervation and amyloid angiopathy in dementia of Alzheimer's type (DAT) as well as signs of selective incomplete white matter infarctions point to a vascular involvement within the degenerative process. In order to investigate potential alterations of cerebrovascular function we performed cerebral blood flow measurements before and after intravenous injection of 1 g acetazolamide using technetium-99m hexamethylpropyleneamine oxime and single photon emission tomography in 12 patients (6 female, 6 male; mean age 70.8 +/- 9.6 years) with probable (senile) dementia of Alzheimer's type (SDAT) and 9 controls (7 female, 2 male; mean age 71.2 +/- 8.6 years). SDAT patients revealed significantly reduced cerebrovascular reactivity with lower values with increasing cognitive impairment. We discuss possible underlying mechanisms.

Acetazolamide↗

PubMedDate not supplied

The joint Task Group on clinical utility of labelled antibodies of the Society of Nuclear Medicine Europa (SNME) and the European Nuclear Medicine Society (ENMS).

In September 1985 a task group on the clinical utility of labelled antibodies was founded by the Society of Nuclear Medicine - Europe. This document was elaborated to report the aims and the programs of the group. In September 1986 the European Nuclear Medicine Society decided to participate in this initiative and a joint task group was created. INITIAL DOCUMENT: A. The aims to the Task Group are to monitor, co-ordinate and promote research and clinical application of techniques using radiolabelled antibodies in nuclear medicine. A.1. The Group should develop into a major point of reference, giving scientific and technical support to each member of the Society involved in this field. B. To pursue these purposes it will be necessary to develop the following: B.1. Criteria to evaluate the suitability of antigen-antibody systems for tumour detection and/or therapy. B.2. Criteria for quality control of radioimmunoreagents. B.3. Criteria for the prevention of adverse reactions or damage due to the reagent. B.4. Selection of suitable dosimetric methods for diagnostic or therapeutic applications. B.5. Elaboration of protocols for clinical experiments, including appropriate techniques to be applied in single cases. B.6. Organization of cooperative studies. C. The Task Group should promote: C.1. Informal meetings between the members of the Group. C.2. Workshops open to the members of the Society and other researchers. C.3. Publication of reports in appropriate journals.

Antibodies, Monoclonal↗

PubMedDate not supplied

A brief guide to the practice of radioimmunoscintigraphy and radioimmunotherapy in cancer. Report of the European Association of Nuclear Medicine Task Group on the clinical utility of labelled antibodies.

Explore the source record for details and available documents.

Animals↗